1. Keepers, GA, Fochtmann, LJ, Anzia, JM, et al The American psychiatric association practice guideline for the treatment of patients with schizophrenia. Am J Psych 2020; 177: 868–872.
Google Scholar | Crossref | Medline2. Meltzer, HY, Gadaleta, E. Contrasting typical and atypical antipsychotic drugs. Focus 2021; 19: 3–13.
Google Scholar | Crossref | Medline3. Carli, M, Kolachalam, S, Longoni, B, et al Atypical antipsychotics and metabolic syndrome: from molecular mechanisms to clinical differences. Pharmaceuticals 2021; 14: 238.
Google Scholar | Crossref | Medline4. Huhn, M, Nikolakopoulou, A, Schneider-Thoma, J, et al Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet 2019; 394: 939–951.
Google Scholar | Crossref | Medline5. Leucht, S, Cipriani, A, Spineli, L, et al Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013; 382: 951–962.
Google Scholar | Crossref | Medline | ISI6. Grinchii, D, Dremencov, E. Mechanism of action of atypical antipsychotic drugs in mood disorders. Int J Mol Sci 2020; 21: 9532.
Google Scholar | Crossref7. Gaviria, AM, Franco, JG, Aguado, V, et al A non-interventional naturalistic study of the prescription patterns of antipsychotics in patients with schizophrenia from the Spanish province of Tarragona. PLoS ONE 2015; 10: e0139403.
Google Scholar | Crossref | Medline8. Marston, L, Nazareth, I, Petersen, I, et al Prescribing of antipsychotics in UK primary care: a cohort study. BMJ Open 2014; 4: e006135.
Google Scholar | Crossref | Medline | ISI9. Keating, D, McWilliams, S, Boland, F, et al Prescribing pattern of antipsychotic medication for first-episode psychosis: a retrospective cohort study. BMJ Open 2021; 11: e040387.
Google Scholar | Crossref | Medline10. Park, S-C, Lee, M-S, Kang, S-G, et al Patterns of antipsychotic prescription to patients with schizophrenia in Korea: results from the health insurance review & assessment service-national patient sample. J Korean Med Sci 2014; 29: 719–728.
Google Scholar | Crossref | Medline | ISI11. Seshadri, M, Elsemary, A, Thalitaya, MD, et al Study on the prescribing patterns of antipsychotic medication in a rural England Community Mental Health Team. Psychiatr Danub 2017; 29: 524–529.
Google Scholar | Medline12. Aringhieri, S, Carli, M, Kolachalam, S, et al Molecular targets of atypical antipsychotics: from mechanism of action to clinical differences. Pharmacol Ther 2018; 192: 20–41.
Google Scholar | Crossref | Medline13. Lee, J, Nurjono, M, Wong, A, et al Prevalence of metabolic syndrome among patients with schizophrenia in Singapore. Ann Acad Med Singap 2012; 41: 457–462.
Google Scholar | Medline14. Vancampfort, D, Stubbs, B, Mitchell, AJ, et al Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry 2015; 14: 339–347.
Google Scholar | Crossref | Medline | ISI15. McCracken, E, Monaghan, M, Sreenivasan, S. Pathophysiology of the metabolic syndrome. Clin Dermatol 2018; 36: 14–20.
Google Scholar | Crossref | Medline16. Mottillo, S, Filion, KB, Genest, J, et al The metabolic syndrome and cardiovascular risk: a systematic review and meta-analysis. J Am Coll Cardiol 2010; 56: 1113–1132.
Google Scholar | Crossref | Medline | ISI17. Regufe, VM, Pinto, CM, Perez, PMVHC. Metabolic syndrome in type 2 diabetic patients: a review of current evidence. Porto Biomed J 2020; 5: e101.
Google Scholar | Crossref | Medline18. Association AD . Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27: 596–601.
Google Scholar19. De Hert, M, Detraux, J, Van Winkel, R, et al Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 2012; 8: 114–126.
Google Scholar | Crossref | ISI20. Perez Rodriguez, A, Tajima-Pozo, K, Lewczuk, A, et al Atypical antipsychotics and metabolic syndrome. Cardiovasc Endocrinol 2015; 4: 132–137.
Google Scholar | Crossref21. Papanastasiou, E. The prevalence and mechanisms of metabolic syndrome in schizophrenia: a review. Ther Adv Psychopharmacol 2013; 3: 33–51.
Google Scholar | SAGE Journals22. Tumiel, E, Wichniak, A, Jarema, M, et al Nonpharmacological interventions for the treatment of cardiometabolic risk factors in people with schizophrenia – a systematic review. Front Psychiatry 2019; 10: 566.
Google Scholar | Crossref | Medline23. Cooper, SJ, Reynolds, GP, Barnes, T, et al BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. J Psychopharmacol 2016; 30: 717–748.
Google Scholar | SAGE Journals | ISI24. Stroup, TS, McEvoy, JP, Ring, KD, et al A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry 2011; 168: 947–956.
Google Scholar | Crossref | Medline | ISI25. Stroup, TS, Byerly, MJ, Nasrallah, HA, et al Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: results from a randomized controlled trial. Schizophr Res 2013; 146: 190–195.
Google Scholar | Crossref | Medline26. Newcomer, JW, Campos, JA, Marcus, RN, et al A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. J Clin Psychiatry 2008; 69: 1046–1056.
Google Scholar | Crossref | Medline | ISI27. Weiden, PJ. Switching antipsychotics as a treatment strategy for antipsychotic-induced weight gain and dyslipidemia. J Clin Psychiatry 2007; 68: 34–39.
Google Scholar | Medline | ISI28. Citrome, L. A systematic review of meta-analyses of the efficacy of oral atypical antipsychotics for the treatment of adult patients with schizophrenia. Expert Opin Pharmacother 2012; 13: 1545–1573.
Google Scholar | Crossref | Medline | ISI29. Meyer, JM, Davis, VG, Goff, DC, et al Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res 2008; 101: 273–286.
Google Scholar | Crossref | Medline | ISI30. Rummel-Kluge, C, Komossa, K, Schwarz, S, et al Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res 2010; 123: 225–233.
Google Scholar | Crossref | Medline | ISI31. Fleischhacker, WW, Heikkinen, ME, Olié, JP, et al Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol 2010; 13: 1115–1125.
Google Scholar | Crossref | Medline | ISI32. Fan, X, Borba, CP, Copeland, P, et al Metabolic effects of adjunctive aripiprazole in clozapine-treated patients with schizophrenia. Acta Psychiatr Scand 2013; 127: 217–226.
Google Scholar | Crossref | Medline | ISI33. Chang, JS, Ahn, Y, Park, HJ, et al Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2008; 69: 720–731.
Google Scholar | Crossref | Medline | ISI34. Henderson, DC, Fan, X, Copeland, PM, et al Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. J Clin Psychopharmacol 2009; 29: 165–169.
Google Scholar | Crossref | Medline | ISI35. Wang, L-J, Ree, S-C, Huang, Y-S, et al Adjunctive effects of aripiprazole on metabolic profiles: comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs. Prog Neuropsychopharmacol Biol Psychiatry 2013; 40: 260–266.
Google Scholar | Crossref | Medline36. Mizuno, Y, Suzuki, T, Nakagawa, A, et al Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis. Schizophr Bull 2014; 40: 1385–1403.
Google Scholar | Crossref | Medline | ISI37. Taylor, DM, Barnes, TR, Young, AH. The Maudsley prescribing guidelines in psychiatry. Newark, NJ: John Wiley & Sons, 2021.
Google Scholar38. Galling, B, Roldan, A, Hagi, K, et al Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. World Psychiatry 2017; 16: 77–89.
Google Scholar | Crossref | Medline39. Gupta, B, LYS Chua, Ong, J, Tan, GCY, et al. Aripiprazole as an adjunct for weight loss in patient’s established on clozapine and olanzapine. In: Singapore health and biomedical congress, Singapore, 2& 3rd October 2015, p. S315. Singapore: Annals of the Academy of Medicine.
Google Scholar40. Kay, SR, Opler, LA, Lindenmayer, JP. The positive and negative syndrome scale (PANSS): rationale and standardisation. Br J Psychiatry Suppl 1989; 7: 59–67.
Google Scholar | Crossref41. Guy, W, editor. Clinician global impression (CGI). In: ECDEU assessment manual for psychopharmacology. US Department of Health, Education, and Welfare Publication (ADM). Rockville, MD: National Institute of Mental Health, 1976, pp. 76–338.
Google Scholar42. Association AP . Diagnostic criteria from DSM-IV-TR. Washington, DC: American Psychiatric Publishing, 2000.
Google Scholar43. Üstün, TB, Kostanjsek, N, Chatterji, S, et al. Measuring health and disability: manual for WHO disability assessment schedule WHODAS 2.0. Geneva: World Health Organization, 2010.
Google Scholar44. Fervaha, G, Agid, O, Foussias, G, et al Toward a more parsimonious assessment of neurocognition in schizophrenia: a 10-minute assessment tool. J Psychiatr Res 2014; 52: 50–56.
Google Scholar | Crossref | Medline | ISI45. Pramyothin, P, Khaodhiar, L. Metabolic syndrome with the atypical antipsychotics. Curr Opin Endocrinol Diabetes Obes 2010; 17: 460–466.
Google Scholar | Crossref | Medline | ISI46. Fleischhacker, WW, Uchida, H. Critical review of antipsychotic polypharmacy in the treatment of schizophrenia. Int J Neuropsychopharmacol 2014; 17: 1083–1093.
Google Scholar | Crossref | Medline | ISI47. Wang, M, Tong, J-H, Zhu, G, et al Metformin for treatment of antipsychotic-induced weight gain: a randomized, placebo-controlled study. Schizophr Res 2012; 138: 54–57.
Google Scholar | Crossref | Medline | ISI48. Boullart, A, de Graaf, J, Stalenhoef, AF. Serum triglycerides and risk of cardiovascular disease. Biochim Biophys Acta 2012; 1821: 867–875.
Google Scholar | Crossref | Medline49. Mailman, RB, Murthy, V. Third generation antipsychotic drugs: partial agonism or receptor functional selectivity? Curr Pharm Des 2010; 16: 488–501.
Google Scholar |